GlassScriptPhysician profile
Annum Faisal
NPI 1871945204
$2,030.22
in general payments reported to CMS, 2019-2025
36 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $264 · 2021: $34.59 · 2022: $79.99 · 2023: $49.56 · 2024: $129 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.18 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $226.03 | 2019-2025 | |
| Incyte Corporation | $201.41 | 2019-2022 | |
| Lilly USA, LLC | $169.72 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Amarin Pharma, INC. | $127.27 | 2019 | |
| Astellas Pharma US INC | $111.00 | 2019-2025 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $110.10 | 2019-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $81.85 | 2019-2025 | Opdivo |
| Amgen INC. | $78.25 | 2019 | |
| Alexion Pharmaceuticals, INC. | $73.07 | 2019-2021 | |
| Janssen Biotech, INC. | $70.58 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $66.83 | 2019-2025 | Reblozyl, Breyanzi |
| Daiichi Sankyo INC. | $58.10 | 2020-2025 | Datroway |
| Pfizer INC. | $54.54 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $51.00 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.35 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.56 | 2021-2025 | Keytruda, Welireg |
| Tempus Ai, INC | $40.74 | 2024-2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $38.72 | 2020-2025 | Ojjaara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.94 | 2019 | |
| Kyowa Kirin, INC. | $34.64 | 2019-2024 | Poteligeo |
| Agios Pharmaceuticals, INC. | $34.50 | 2019-2020 | |
| Eisai INC. | $31.22 | 2019-2020 | |
| Beone Medicines USA, INC. | $28.75 | 2025 | Brukinsa |
| Tesaro, INC. | $25.73 | 2019 | |
| Btg International INC. | $25.46 | 2019 | |
| Stemline Therapeutics INC. | $25.02 | 2023 | Orserdu |
| Tersera Therapeutics LLC | $18.89 | 2020 | |
| Shire North American Group INC | $18.21 | 2019 | |
| Abbvie INC. | $16.07 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $15.38 | 2020 | |
| Seagen INC. | $13.84 | 2019 | |
| Pharmaessentia USA Corporation | $13.72 | 2025 | Besremi |
| Karyopharm Therapeutics INC. | $13.46 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.67 | 2020 | |
| Genentech USA, INC. | $11.80 | 2019 | |
| Secura Bio, INC. | $9.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annum Faisal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.